ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

Cancer Letters, a leading journal published by Elsevier Ireland Ltd, is dedicated to advancing the field of oncology and cancer research. With a rich history that spans from 1975 to 2024, this esteemed journal has established itself as a vital resource within the scientific community, holding a prestigious Q1 status in both Cancer Research and Oncology categories as of 2023. With an impressive ranking of #26/404 in Medicine _ Oncology and #19/230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, Cancer Letters sits in the top percentiles of its field, reflecting its high impact and relevance. Although it does not currently offer open access, the journal remains committed to disseminating paramount research findings, innovative methodologies, and critical reviews that inform and enhance ongoing studies in cancer therapeutics and patient care. Researchers, professionals, and students alike will find invaluable insights into the latest developments and discoveries in cancer research through the pages of Cancer Letters.

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.